GeneCode AS
GeneCode AS is an Estonian preclinical-stage pharmaceutical company developing orally bioavailable small-molecule GDNF mimetics for Parkinson's disease, ALS, inflammatory bowel disease, and retinitis pigmentosa. The platform pursues disease-modifying therapies via GFRα1/RET receptor agonism, funded through EU and Estonian grants and targeting future pharma licensing agreements.
- Company typePrivate
- Founded1993
- HeadquartersTallinn, Estonia
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What GeneCode AS does
GeneCode AS (legal entity GeneCode Ltd.) is an Estonian preclinical-stage pharmaceutical company headquartered in Tallinn that develops small-molecule drugs designed to activate the GDNF (Glial cell line-Derived Neurotrophic Factor) receptor complex (GFRα1/RET) and thereby protect or restore neurons in neurodegenerative and related diseases. Its science originated in Prof. Mart Saarma's laboratory at the University of Helsinki, where the crystal structure of the GDNF/GFRα1 receptor complex was solved, enabling rational small-molecule design; a proprietary high-throughput luciferase assay was then used to screen over 30,000 compounds from the company's chemical library, yielding lead candidates (including BT13) reported to be more potent than natural GDNF and capable of crossing the blood-brain barrier for oral systemic delivery.
The product portfolio currently comprises a GDNF Mimetics Platform and four indication-targeted drug candidate programs: RET agonists for Parkinson's disease (the primary lead), GDNF mimetics for amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, and inflammatory bowel disease (IBD). Parkinson's disease is the most advanced program, targeting both motor and non-motor symptoms via weekly or less-frequent oral dosing and designed as the first disease-modifying rather than symptomatic therapy. The IP base includes 50+ patent families, and the underlying research is supported by 600+ peer-reviewed publications with 30,000+ citations.
GeneCode generates no commercial product revenue today; its economics rest on non-dilutive grant funding (Enterprise Estonia, Estonian Business and Innovation Agency, EU Regional Development Fund) plus a single €14.3M equity tranche inside the €16M EIC Accelerator award received in 2023. Its go-to-market is event- and partnership-driven — Argobio co-develops the Kevad Bio Parkinson's project, and the company participates in EU forums such as Healthcare Transformation Forum and Medtech Impact 2025 — with the explicit commercial endpoint being licensing or co-development agreements with major pharmaceutical companies for clinical development, regulatory approval, and global commercialization of disease-modifying therapies in Parkinson's disease, ALS, IBD, and retinitis pigmentosa.
GeneCode AS firmographics
Firmographics- Name
- GeneCode AS
- Legal name
- GeneCode Ltd.
- Website
- https://genecode.com
- Company type
- Private
- Founded year
- 1993
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- GeneCode AS is an Estonian preclinical-stage pharmaceutical company developing orally bioavailable small-molecule GDNF mimetics for Parkinson's disease, ALS, inflammatory bowel disease, and retinitis pigmentosa. The platform pursues disease-modifying therapies via GFRα1/RET receptor agonism, funded through EU and Estonian grants and targeting future pharma licensing agreements.
- Ownership category
- akta.pro rank
GeneCode AS industry classification
Industry- Product category
- Neurodegenerative Disease Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Cheminformatics & Molecular Modeling / CADD (HLAGAJAE), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where GeneCode AS is headquartered
LocationHeadquarters
- HQ city
- Tallinn
- HQ country
- Estonia
- HQ region
- Europe
Offices1 record
Markets served
GeneCode AS business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Pharmaceutical Drug Development and Licensing: As a preclinical-stage pharmaceutical company, GeneCode is developing small-molecule drugs for neurodegenerative diseases. Revenue will be generated through licensing agreements, co-development partnerships with pharmaceutical companies, and eventual product sales following regulatory approval. The company has received significant grant and equity funding from EU and Estonian sources to advance clinical development.
- Government Grants and Non-dilutive Funding: GeneCode has secured multiple grants including €16M from EIC Accelerator (split as €1.7M grant and €14.3M equity), €1.5M from Estonian Business and Innovation Agency, €1.6M from Enterprise Estonia, and €2M R&D Grant from Enterprise Estonia. These grants support preclinical research and IND-enabling studies.
Go-to-market motion2 records
Marketing channels5 records
GeneCode AS product offering
Product offeringCore offering
GeneCode AS is a preclinical-stage pharmaceutical company developing small-molecule drugs that activate GDNF receptors (GFRα1/RET complex) to protect and restore neurons. Its lead program targets disease-modifying treatment of Parkinson's disease via orally bioavailable RET agonists that cross the blood-brain barrier, with additional programs in ALS, inflammatory bowel disease, and retinitis pigmentosa. The company leverages a proprietary GDNF Mimetics Platform built on the resolved crystal structure of the GDNF/GFRα1 receptor complex and high-throughput screening of 30,000+ compounds.
Product overview
GeneCode is a preclinical-stage pharmaceutical company developing a GDNF Mimetics Platform that enables the discovery and development of small molecule drugs targeting GDNF (glial cell line-derived neurotrophic factor) receptors. The company's lead program focuses on RET agonists for Parkinson's disease treatment, with the platform also being applied to develop candidates for ALS, retinitis pigmentosa, and inflammatory bowel disease. The GDNF Mimetics Platform was used to screen over 30,000 compounds, identifying lead candidates now advancing into IND-enabling studies. Key drug candidates include BT13, a novel small molecule GDNF receptor RET agonist.
Differentiator
Problem solved
Functional benefit
Products and services
- GDNF Mimetics Platform Proprietary drug discovery platform that identifies and develops small molecule compounds activating GDNF receptors (GFRα1/RET complex) to mimic neurotrophic factor activity for treatment of neurodegenerative diseases. Built on the resolved GDNF/GFRα1 receptor crystal structure and a high-throughput luciferase assay screening 30,000+ compounds; for internal pipeline use and partnership with pharmaceutical companies.
- RET Agonists for Parkinson's Disease Small molecule RET receptor agonists targeting the GFRα1-RET complex for disease-modifying treatment of Parkinson's disease, designed to cross the blood-brain barrier and be administered orally, addressing both motor and non-motor symptoms.
- GDNF Mimetics for ALS Small molecule GDNF receptor agonist drug candidates being developed as a neuroprotective therapy for amyotrophic lateral sclerosis (ALS), targeting motor neuron survival.
- GDNF Mimetics for Retinitis Pigmentosa GDNF receptor agonist compounds being explored as a neuroprotective therapy for retinitis pigmentosa, targeting progressive dysfunction of retinal rod and cone photoreceptor cells.
- GDNF Mimetics for Inflammatory Bowel Disease GDNF receptor agonist compounds being explored for treatment of inflammatory bowel disease (Crohn's disease and ulcerative colitis), targeting intestinal epithelium barrier dysfunction.
- BT13 Compound Novel small molecule GDNF receptor RET agonist discovered by GeneCode, shown to promote neurite growth from sensory neurons and demonstrating neuroprotective effects in Parkinson's disease models.
Quantifiable outcome
- Neuroprotective effects demonstrated in both animal models of Parkinson's disease and laboratory models using human dopamine neurons
- +2 more outcomes
Companies that use GeneCode AS
Customer profileSegments4 records
Ideal customer profiles2 records
GeneCode AS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
GeneCode AS partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- ArgobiocoreGeneCode partnered with Argobio on Parkinson's Disease research in Argobio's first announced research agreement. The collaboration focuses on the Kevad Bio project developing GDNF mimetics for Parkinson's disease treatment. Argobio is a biotech studio that provides operational support and resources for early-stage biotech companies.
- University of HelsinkicoreGeneCode collaborates with the Institute of Biotechnology, HiLIFE, University of Helsinki where Prof. Dr. Mart Saarma serves as research director and professor. The collaboration provides access to cutting-edge neuroscience research and facilities for neurotrophic factor studies.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
GeneCode AS competitors and assessment
Company assessmentDirect peers
- Herantis Pharma: Finnish clinical-stage biotech developing CDNF (cerebral dopamine neurotrophic factor) protein therapy for Parkinson's disease — directly comparable given GeneCode's co-founder Prof. Saarma's relationship to CDNF and the overlapping neurotrophic factor / Parkinson's disease-modifying mechanism.
- Prilenia Therapeutics: Clinical-stage biotech developing pridopidine, a small molecule targeting neurodegenerative diseases including Parkinson's and ALS — comparable as a small-molecule neuroprotective approach for overlapping indications.
- Neuraly (D&D Pharmatech): Clinical-stage biotech developing neuroprotective small molecules (e.g., NLY01) for Parkinson's and ALS — directly comparable in modality, mechanism (neuroprotection), and indication focus.
Regional players
- BioArctic AB: Swedish biotech developing disease-modifying therapies for neurodegenerative diseases including Parkinson's, with lecanemab partnership with Eisai — a regional peer targeting the same indications with biologics approaches.
Broad incumbents
- Denali Therapeutics: US clinical-stage biotech developing small molecules and biologics for neurodegeneration including Parkinson's and ALS — broader but directly comparable therapeutic-area focus and modality overlap (small molecule CNS).
- Cerevel Therapeutics: Clinical-stage neuroscience company developing small molecules for Parkinson's disease and other CNS disorders — comparable in modality (small molecule CNS) and indication focus, though at later clinical stage.
- Prevail Therapeutics: Acquired by Lilly; develops AAV-based gene therapies for Parkinson's and other neurodegenerative diseases — comparable target indication but different modality (gene therapy vs. small molecule).
- Ionis Pharmaceuticals: Established US biotech developing antisense oligonucleotide therapies for neurological diseases including Parkinson's and ALS — relevant adjacent player addressing the same disease-modifying neuro indication space.
- Sage Therapeutics: Commercial-stage CNS biotech with zuranolone approved; pursues small-molecule neurotherapeutics — comparable in CNS small-molecule focus, though broader and commercially more mature.
Others
- Argobio Studio: European biotech studio that incubates and co-develops early-stage biotech companies; partnered with GeneCode on the Kevad Bio project — relevant as a partner and indirect comparable in the EU biotech-creation ecosystem.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
GeneCode AS social profiles
Digital presenceGeneCode AS financial estimates
Financial estimateRevenue estimate
Valuation estimate
GeneCode AS leadership team
Management profileNumber of profiles
Profiles9 records
GeneCode AS funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GeneCode AS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GeneCode AS
What does GeneCode AS do?
GeneCode AS is a preclinical-stage pharmaceutical company developing small-molecule drugs that activate GDNF receptors (GFRα1/RET complex) to protect and restore neurons. Its lead program targets disease-modifying treatment of Parkinson's disease via orally bioavailable RET agonists that cross the blood-brain barrier, with additional programs in ALS, inflammatory bowel disease, and retinitis pigmentosa. The company leverages a proprietary GDNF Mimetics Platform built on the resolved crystal structure of the GDNF/GFRα1 receptor complex and high-throughput screening of 30,000+ compounds.
Is GeneCode AS a public or private company?
GeneCode AS is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was GeneCode AS founded?
GeneCode AS was founded in 1993. It employs 1 to 10 people.
Where is GeneCode AS based?
GeneCode AS is headquartered in Tallinn, Estonia, in the Europe region.
How does GeneCode AS make money?
Two revenue lines are on record. Pharmaceutical Drug Development and Licensing is the primary driver. The others are government Grants and Non-dilutive Funding.
Who are GeneCode AS's main competitors?
Direct peers on record are Herantis Pharma, Prilenia Therapeutics and Neuraly (D&D Pharmatech). BioArctic AB is listed as a regional player. Broad incumbents are Denali Therapeutics, Cerevel Therapeutics, Prevail Therapeutics, Ionis Pharmaceuticals and Sage Therapeutics. Argobio Studio is listed as an others.
Does GeneCode AS have an API?
No public API is recorded for GeneCode AS.
What industry is GeneCode AS in?
GeneCode AS's product category is Neurodegenerative Disease Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAGAJAE, Cheminformatics & Molecular Modeling / CADD. Its NAICS code is 541714 and its SIC code is 2834.